生物技术公司Artiva Biotherapeutics宣布，其核心产品Allonk®在针对多种自身免疫性疾病的早期临床研究中取得突破性进展。数据显示该疗法在安全性及有效性方面均表现出积极信号。与此同时，公司已与美国食品药品监督管理局（FDA）就开展类风湿关节炎的三期注册临床试验达成关键共识，预计将于2026年正式启动这项关键性研究。
生物技术公司Artiva Biotherapeutics宣布，其核心产品Allonk®在针对多种自身免疫性疾病的早期临床研究中取得突破性进展。数据显示该疗法在安全性及有效性方面均表现出积极信号。与此同时，公司已与美国食品药品监督管理局（FDA）就开展类风湿关节炎的三期注册临床试验达成关键共识，预计将于2026年正式启动这项关键性研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.